A detailed history of Mitchell Sinkler & Starr transactions in Eli Lilly & CO stock. As of the latest transaction made, Mitchell Sinkler & Starr holds 3,066 shares of LLY stock, worth $2.35 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
3,066
Previous 2,667 14.96%
Holding current value
$2.35 Million
Previous $2.41 Million 12.51%
% of portfolio
0.64%
Previous 0.62%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$772.14 - $960.02 $308,083 - $383,047
399 Added 14.96%
3,066 $2.72 Million
Q2 2024

Aug 07, 2024

SELL
$724.87 - $909.04 $822,727 - $1.03 Million
-1,135 Reduced 29.85%
2,667 $2.41 Million
Q1 2024

Apr 30, 2024

SELL
$592.2 - $792.28 $6.13 Million - $8.21 Million
-10,359 Reduced 73.15%
3,802 $2.96 Million
Q4 2023

Feb 12, 2024

BUY
$525.19 - $619.13 $3 Million - $3.53 Million
5,704 Added 67.45%
14,161 $8.25 Million
Q3 2023

Nov 01, 2023

BUY
$434.7 - $599.3 $2.69 Million - $3.71 Million
6,198 Added 274.37%
8,457 $4.54 Million
Q2 2023

Jul 18, 2023

SELL
$350.74 - $468.98 $89,087 - $119,120
-254 Reduced 10.11%
2,259 $1.06 Million
Q1 2023

May 15, 2023

SELL
$310.63 - $364.82 $247,572 - $290,761
-797 Reduced 24.08%
2,513 $863,000
Q4 2022

Feb 14, 2023

BUY
$321.55 - $374.67 $11,254 - $13,113
35 Added 1.07%
3,310 $1.21 Million
Q3 2022

Oct 25, 2022

SELL
$296.48 - $337.87 $126,004 - $143,594
-425 Reduced 11.49%
3,275 $1.06 Million
Q1 2022

Apr 19, 2022

BUY
$234.69 - $291.66 $224,833 - $279,410
958 Added 34.94%
3,700 $1.06 Million
Q4 2021

Feb 01, 2022

SELL
$224.85 - $279.04 $134,910 - $167,424
-600 Reduced 17.95%
2,742 $757,000
Q1 2021

Apr 12, 2021

SELL
$164.32 - $212.72 $131,456 - $170,176
-800 Reduced 19.31%
3,342 $624,000
Q3 2020

Oct 07, 2020

SELL
$146.22 - $169.13 $228,103 - $263,842
-1,560 Reduced 27.36%
4,142 $613,000
Q1 2020

Apr 07, 2020

SELL
$119.05 - $147.35 $47,620 - $58,940
-400 Reduced 6.56%
5,702 $791,000
Q4 2019

Jan 09, 2020

SELL
$106.92 - $132.43 $150,757 - $186,726
-1,410 Reduced 18.77%
6,102 $802,000
Q2 2019

Jul 17, 2019

SELL
$110.79 - $129.32 $36,560 - $42,675
-330 Reduced 4.21%
7,512 $832,000
Q1 2019

Apr 08, 2019

SELL
$111.31 - $131.02 $63,001 - $74,157
-566 Reduced 6.73%
7,842 $1.02 Million
Q4 2018

Jan 24, 2019

SELL
$105.9 - $118.64 $281,482 - $315,345
-2,658 Reduced 24.02%
8,408 $973,000
Q2 2018

Jul 11, 2018

SELL
$75.7 - $86.88 $28,236 - $32,406
-373 Reduced 3.26%
11,066 $944,000
Q1 2018

Apr 13, 2018

BUY
$74.21 - $87.6 $848,888 - $1 Million
11,439 New
11,439 $885,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Mitchell Sinkler & Starr Portfolio

Follow Mitchell Sinkler & Starr and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitchell Sinkler & Starr, based on Form 13F filings with the SEC.

News

Stay updated on Mitchell Sinkler & Starr with notifications on news.